Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

02.05.2023 - NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) - Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today ... Seite 1

Related Keywords

,Phasei Trial ,Adult Patients ,Acute Myeloid ,Production Advances ,Targeting Hematologic ,Solid Tumor ,